MCID: RFR008
MIFTS: 33

Refractory Anemia with Excess Blasts

Categories: Blood diseases, Rare diseases

Aliases & Classifications for Refractory Anemia with Excess Blasts

MalaCards integrated aliases for Refractory Anemia with Excess Blasts:

Name: Refractory Anemia with Excess Blasts 59

Characteristics:

Orphanet epidemiological data:

59
refractory anemia with excess blasts
Inheritance: Not applicable; Age of onset: Adult;

Classifications:



External Ids:

Orphanet 59 ORPHA86839
MESH via Orphanet 45 D000754
UMLS via Orphanet 74 C0002894
ICD10 via Orphanet 34 D46.2

Summaries for Refractory Anemia with Excess Blasts

MalaCards based summary : Refractory Anemia with Excess Blasts is related to refractory anemia and myeloid leukemia. An important gene associated with Refractory Anemia with Excess Blasts is TET2 (Tet Methylcytosine Dioxygenase 2), and among its related pathways/superpathways is Hematopoietic Stem Cell Differentiation. The drugs Lenograstim and Fludarabine have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow.

Wikipedia : 76 Myelodysplastic syndromes (MDS) are a group of cancers in which immature blood cells in the bone marrow... more...

Related Diseases for Refractory Anemia with Excess Blasts

Graphical network of the top 20 diseases related to Refractory Anemia with Excess Blasts:



Diseases related to Refractory Anemia with Excess Blasts

Symptoms & Phenotypes for Refractory Anemia with Excess Blasts

Drugs & Therapeutics for Refractory Anemia with Excess Blasts

Drugs for Refractory Anemia with Excess Blasts (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 227)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
2
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751
3
Etoposide Approved Phase 2, Phase 3,Phase 3,Phase 1 33419-42-0 36462
4
Cytarabine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 147-94-4 6253
5
Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
6
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
7
Idarubicin Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 58957-92-9 42890
8
Prednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 50-24-8 5755
9
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 65271-80-9 4212
10
Daunorubicin Approved Phase 2, Phase 3,Phase 3,Phase 1 20830-81-3 30323
11
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 83-43-2 6741
12
Azacitidine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 320-67-2 9444
13
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
14
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
15
Arsenic trioxide Approved, Investigational Phase 2, Phase 3,Phase 1 1327-53-3 518740
16
alemtuzumab Approved, Investigational Phase 2, Phase 3,Phase 1 216503-57-0
17
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
18
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904
19
Hydroxyurea Approved Phase 3 127-07-1 3657
20
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
21
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
22
Clofarabine Approved, Investigational Phase 2, Phase 3 123318-82-1 119182
23
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
24
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
25
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
26
Tacrolimus Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 104987-11-3 445643 439492
27
Melphalan Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 148-82-3 4053 460612
28
Thioguanine Approved Phase 3 154-42-7 2723601
29
Aldesleukin Approved Phase 3,Phase 1,Phase 2 85898-30-2, 110942-02-4
30
nivolumab Approved Phase 2, Phase 3 946414-94-4
31
Coal tar Approved Phase 2, Phase 3 8007-45-2
32
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
33
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 1,Phase 2 302-79-4 5538 444795
34
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
35
tipifarnib Investigational Phase 3,Phase 2,Phase 1 192185-72-1 159324
36 Staurosporine Experimental Phase 2, Phase 3,Phase 1 62996-74-1
37
Butyric Acid Experimental, Investigational Phase 3 107-92-6 264
38 Prednisolone acetate Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
39 Dexamethasone acetate Phase 3,Phase 2 1177-87-3
40 Epoetin alfa Phase 2, Phase 3 113427-24-0
41 Analgesics Phase 3,Phase 2,Phase 1,Not Applicable
42 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
43 glucocorticoids Phase 3,Phase 2,Phase 1,Not Applicable
44 Methylprednisolone acetate Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
45 Methylprednisolone Hemisuccinate Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
46 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1,Not Applicable
47 Mitogens Phase 3,Phase 2,Phase 1
48 Gastrointestinal Agents Phase 3,Phase 2,Phase 1,Not Applicable
49 Gemtuzumab Phase 3,Phase 2
50 Neuroprotective Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 193)
# Name Status NCT ID Phase Drugs
1 Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes Unknown status NCT01196715 Phase 3 Darbepoetin alpha;Filgrastim
2 Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS) Unknown status NCT00234143 Phase 2, Phase 3 Darbepoetin
3 Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T Unknown status NCT00209833 Phase 2, Phase 3 Cytarabine;Idarubicin;Etoposide;Fludarabine;G-CSF;Daunorubicine
4 Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00003602 Phase 3 cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
5 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Unknown status NCT00002926 Phase 3 cytarabine;etoposide;idarubicin
6 Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome Unknown status NCT00043134 Phase 3 decitabine
7 Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
8 Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
9 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
10 S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia Completed NCT00005866 Phase 3 busulfan;cyclophosphamide;cyclosporine;methotrexate
11 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia Completed NCT00003436 Phase 3 amsacrine;asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;methotrexate;mitoxantrone hydrochloride;therapeutic hydrocortisone
12 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
13 Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma Completed NCT00003187 Phase 2, Phase 3 cyclophosphamide;cyclosporine;cytarabine;methotrexate;methylprednisolone
14 Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation Completed NCT00004255 Phase 2, Phase 3 cyclophosphamide;fludarabine phosphate;methylprednisolone;tacrolimus
15 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
16 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
17 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
18 Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome Completed NCT00004208 Phase 3 ATG + CSA
19 Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission Completed NCT00093470 Phase 3 Tipifarnib
20 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
21 G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT Recruiting NCT02744742 Phase 2, Phase 3 Decitabine;Busulfan (BU);Cyclophosphamide (CY);Granulocyte Colony-Stimulating Factor(G-CSF)
22 Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA Recruiting NCT02562443 Phase 3 rigosertib;Any approved or standard-of-care therapy;best supportive care (BSC);best supportive care (BSC)
23 Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Recruiting NCT03092674 Phase 2, Phase 3 Azacitidine;Cytarabine;Decitabine;Midostaurin
24 Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine Active, not recruiting NCT01928537 Phase 3 rigosertib sodium
25 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
26 A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia. Terminated NCT00363025 Phase 3 Idarubicin versus daunorubicin
27 Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome Unknown status NCT00003123 Phase 2 amifostine trihydrate
28 Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome Unknown status NCT00017550 Phase 2
29 Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome Unknown status NCT00003827 Phase 2 amifostine trihydrate;cytarabine;topotecan hydrochloride
30 Gemtuzumab in Treating Patients With Myelodysplastic Syndrome Unknown status NCT00022321 Phase 2 gemtuzumab ozogamicin
31 Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes Unknown status NCT00020969 Phase 2 arsenic trioxide
32 Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome Unknown status NCT00513578 Phase 2
33 Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Unknown status NCT00425477 Phase 2 bexarotene
34 Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome Unknown status NCT00003681 Phase 2 amifostine trihydrate
35 Amifostine and High-Dose Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Chronic Myelogenous Leukemia Unknown status NCT00003407 Phase 2 amifostine trihydrate;cytarabine;mitoxantrone hydrochloride
36 Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML Completed NCT00854945 Phase 1, Phase 2 ON 01910.Na
37 Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy Completed NCT00005942 Phase 1, Phase 2 liposomal daunorubicin citrate;semaxanib
38 Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome Completed NCT00003415 Phase 1, Phase 2 amifostine trihydrate;topotecan hydrochloride
39 Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies Completed NCT01175785 Phase 2 fludarabine phosphate;cyclophosphamide;cyclosporine;mycophenolate mofetil
40 Thalidomide in Treating Patients With Myelodysplastic Syndrome Completed NCT00015990 Phase 2 thalidomide
41 Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome Completed NCT00004918 Phase 1, Phase 2 Montanide ISA 51 VG
42 Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia Completed NCT00096122 Phase 1, Phase 2 cytarabine;idarubicin;tipifarnib
43 CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase Completed NCT00084916 Phase 2 temsirolimus
44 Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation Completed NCT00052520 Phase 1, Phase 2
45 Safety and Tolerability Trial of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor Hematopoietic Stem Cell Transplant Completed NCT01012492 Phase 2 Abatacept
46 Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes Completed NCT00352001 Phase 1, Phase 2 azacitidine;lenalidomide
47 Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome Completed NCT01165996 Phase 1, Phase 2 decitabine
48 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
49 Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm Completed NCT01101880 Phase 2 clofarabine;cytarabine
50 Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes Completed NCT00274781 Phase 2 arsenic trioxide;gemtuzumab ozogamicin

Search NIH Clinical Center for Refractory Anemia with Excess Blasts

Genetic Tests for Refractory Anemia with Excess Blasts

Anatomical Context for Refractory Anemia with Excess Blasts

MalaCards organs/tissues related to Refractory Anemia with Excess Blasts:

41
Myeloid, Bone, Bone Marrow, T Cells, Kidney, Testes, Endothelial

Publications for Refractory Anemia with Excess Blasts

Articles related to Refractory Anemia with Excess Blasts:

(show all 45)
# Title Authors Year
1
[Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)]. ( 29070129 )
2017
2
Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States. ( 27558206 )
2016
3
Azacitidine versus decitabine in patients with refractory anemia with excess blast-Results of multicenter study. ( 27107658 )
2016
4
Low Dose Cytosine Arabinoside and Azacitidine Combination in Elderly Patients with Acute Myeloid Leukemia and Refractory Anemia with Excess Blasts (MDS-RAEB2). ( 26855506 )
2016
5
Acquired elliptocytosis in the setting of a refractory anemia with excess blasts and del(20q). ( 28092889 )
2016
6
Isolated trisomy 13 in refractory anemia with excess blasts: report of two cases and a brief literature review of this possible association. ( 26133721 )
2015
7
Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG). ( 26400023 )
2015
8
Proteome changes in the plasma of myelodysplastic syndrome patients with refractory anemia with excess blasts subtype 2. ( 24958999 )
2014
9
Durable second complete remissions with oral melphalan in hypocellular Acute Myeloid Leukemia and Refractory Anemia with Excess Blast with normal karyotype relapsing after intensive chemotherapy. ( 24371768 )
2013
10
Plasma protein alterations in the refractory anemia with excess blasts subtype 1 subgroup of myelodysplastic syndrome. ( 22568928 )
2012
11
Identification of genes underlying different methylation profiles in refractory anemia with excess blast and refractory cytopenia with multilineage dysplasia in myelodysplastic syndrome. ( 23071473 )
2012
12
Pilot study on combination of azacitidine and low-dose cytarabine for patients with refractory anemia with excess blast. ( 21947085 )
2012
13
Immunologic characteristics and prognosis of myelodysplastic syndrome new subtype: refractory anemia with excess blasts-II. ( 19236759 )
2009
14
Chronic myelomonocytic leukemia with antecedent refractory anemia with excess blasts: further evidence for the arbitrary nature of current classification systems. ( 18604717 )
2008
15
Donor lymphocyte infusions for post-transplant relapse of refractory anemia with excess blasts and monosomy 7. ( 17253642 )
2008
16
Copper deficiency with increased hematogones mimicking refractory anemia with excess blasts. ( 17706281 )
2008
17
An antecedent diagnosis of refractory anemia with excess blasts has no influence on mobilization of peripheral blood stem cells and hematopoietic recovery after autologous stem cell transplantation in acute myeloid leukemia. ( 17042770 )
2007
18
An antecedent diagnosis of refractory anemia with excess blasts has no prognostic relevance in acute myeloid leukemia of older adult patients. ( 16687417 )
2006
19
Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts. ( 12857550 )
2003
20
A cytochemical note on nucleoli of granulocytic precursors and granulocytes in patients suffering from the refractory anemia with excess blasts (RAEB) of the myelodysplastic syndrome (MDS). ( 12044061 )
2002
21
More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia. ( 12399969 )
2002
22
HIV and refractory anemia with excess blasts (RAEB). ( 12210814 )
2002
23
Re-evaluation of refractory anemia with excess blasts in transformation. ( 11597728 )
2001
24
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. ( 11739159 )
2001
25
Differences between refractory anemia with excess blasts in transformation and acute myeloid leukemia. ( 10939804 )
2000
26
Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. ( 10846828 )
2000
27
Translocation (5;18) in a patient with myelodysplastic syndrome: refractory anemia with excess blasts in transformation. ( 11203251 )
2000
28
5q- in a child with refractory anemia with excess blasts: similarities to 5q- syndrome in adults. ( 9723027 )
1998
29
Severe hypodiploidy in refractory anemia with excess blasts in transformation. ( 9723043 )
1998
30
Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. ( 9376577 )
1997
31
On a dramatic response of refractory anemia with excess blasts in transformation to 5-azacytidine. ( 7539583 )
1995
32
High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF). ( 9384660 )
1995
33
Lineage-unrestricted hematologic response to granulocyte colony-stimulating factor in a patient with refractory anemia with excess blasts. ( 7536478 )
1995
34
5q- chromosome. Evidence for complex interstitial breaks in a case of refractory anemia with excess blasts. ( 8194054 )
1994
35
Trisomy 8 and 11 in refractory anemia with excess blasts in transformation (RAEB-T). ( 1521244 )
1992
36
Trisomy 14 in refractory anemia with excess blasts in transformation. ( 1555198 )
1992
37
Complex chromosomal abnormalities in a patient with refractory anemia with excess blasts (RAEB). ( 1884355 )
1991
38
Dissociation between In-111 chloride and Tc-99m colloid bone marrow scintigraphy in refractory anemia with excess blasts. ( 2311325 )
1990
39
Formation of double minutes by breakdown of a homogeneously staining region in a refractory anemia with excess blasts. ( 3395993 )
1988
40
Disturbances of T lymphocyte subsets preceding refractory anemia with excess blasts in transformation in a child. ( 3124467 )
1988
41
Translocation t(6;9)(p22.3;q34) in myelodysplastic syndrome--refractory anemia with excess blasts. ( 3664444 )
1987
42
Duplication of one of the products of the t(8;21) translocation in a patient with refractory anemia with excess blasts in transformation. ( 3802052 )
1987
43
Dysmyelopoiesis in the cat: a hematological disorder resembling refractory anemia with excess blasts in man. ( 3742354 )
1986
44
Multinucleate megakaryocytes in refractory anemia with excess blasts. ( 6687675 )
1983
45
A phase II study of prednimustine in acute non-lymphocytic leukemia, smouldering leukemia, and refractory anemia with excess blasts. ( 7139848 )
1982

Variations for Refractory Anemia with Excess Blasts

Expression for Refractory Anemia with Excess Blasts

Search GEO for disease gene expression data for Refractory Anemia with Excess Blasts.

Pathways for Refractory Anemia with Excess Blasts

Pathways related to Refractory Anemia with Excess Blasts according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.3 CSF3 GATA2

GO Terms for Refractory Anemia with Excess Blasts

Biological processes related to Refractory Anemia with Excess Blasts according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 animal organ morphogenesis GO:0009887 9.26 ASXL1 GATA2
2 hemopoiesis GO:0030097 9.16 ASXL1 GATA2
3 negative regulation of fat cell differentiation GO:0045599 8.96 ASXL1 GATA2
4 positive regulation of transcription by RNA polymerase II GO:0045944 8.92 ASXL1 CSF3 GATA2 TET2

Sources for Refractory Anemia with Excess Blasts

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....